Royalty Pharma EVP Marshall Urist sells 4,126 shares

The executive vice president's sale was reported under a Rule 10b5-1 plan adopted on June 26, 2026.

Rhea-AI Filing Summary

Royalty Pharma plc (RPRX) EVP, Research & Investments Marshall Urist sold 4,126 Class A Ordinary Shares on September 28, 2026, at $57.88 per share under a Rule 10b5-1 plan adopted June 26, 2026. After the sale, he reported 4,126 shares held directly and 19,020 shares held indirectly through an IRA.

Separately, Urist and family vehicles controlled by him reported limited partnership interests exchangeable into 2,444,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd. exchangeable into 1,356,528 Class A Ordinary Shares. The Class E Ordinary Shares are subject to vesting conditions.

Insider Trade Summary 10b5-1

Net Seller: 4,126 shares

Net Sell 2 txns

Insider Urist Marshall

Role EVP, Research & Investments

Sold 4,126 shs ($239K)

Type	Security	Shares	Price	Value
Sale	Class A Ordinary Shares F1	4,126	$57.88	$239K
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 4,126 shares (Direct); Class A Ordinary Shares — 19,020 shares (Indirect, By IRA)

Footnotes (1)

1. F1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on June 26, 2026.

Key Figures

Class A Ordinary Shares sold: 4,126 shares Sale price per share: $57.88 per share Direct Class A Ordinary Shares after sale: 4,126 shares +3 more

6 metrics

Class A Ordinary Shares sold 4,126 shares September 28, 2026

Sale price per share $57.88 per share September 28, 2026

Direct Class A Ordinary Shares after sale 4,126 shares Reported after the September 28, 2026 sale

Indirect Class A Ordinary Shares held through IRA 19,020 shares Reported as of September 28, 2026

Class A Ordinary Shares exchangeable from RPI US Partners 2019, LP interests 2,444,120 shares Interests held by Marshall Urist and family vehicles controlled by him

Class A Ordinary Shares exchangeable from RPH Class E Ordinary Shares 1,356,528 shares Class E Ordinary Shares are subject to vesting conditions

Key Terms

Rule 10b5-1 plan, limited partnership interests, vesting conditions

3 terms

Rule 10b5-1 plan regulatory

"transactions were effected pursuant to a 10b5-1 plan adopted"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

limited partnership interests financial

"hold limited partnership interests in RPI US Partners 2019, LP"

An ownership stake in a limited partnership gives an investor the role of a limited partner who provides capital but does not run day-to-day operations; a separate general partner manages the business. It matters because limited partners share profits, losses, and tax benefits but generally cannot lose more than they invested and have little control or liquidity—think of it like quietly funding a small business while someone else manages it, with potential return and risk tied to the venture’s performance.

vesting conditions financial

"Class E Ordinary Shares of RPH are subject to vesting conditions"

Vesting conditions are the rules that determine when someone earning company stock or stock options actually gains the right to keep or sell them, typically based on staying with the company for a set time or meeting performance targets. Think of it like keys that unlock gradually — some unlock by calendar date, others only after agreed milestones. Investors care because vesting shapes management incentives, the timing of share sales, and the number of shares that can enter the market, which can affect a company's valuation and ownership mix.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many RPRX shares did Marshall Urist sell, and at what price?

Marshall Urist sold 4,126 Class A Ordinary Shares at $57.88 per share on September 28, 2026, under a Rule 10b5-1 plan adopted June 26, 2026.

What RPRX shares did Marshall Urist report holding after the sale?

After the sale, Marshall Urist reported 4,126 Class A Ordinary Shares held directly and 19,020 shares held indirectly through an IRA.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/30/2026 - 04:32 PM Accepted by SEC EDGAR 09/30/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Urist Marshall

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Research & Investments

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	09/28/2026		S(1)		4,126	D	$57.88	4,126	D
Class A Ordinary Shares								19,020	I	By IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on June 26, 2026.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 2,444,120 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 1,356,528 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact, for Marshall Urist	09/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)